Signaling by FGFR2 amplification mutants
Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A, Ashworth A, van de Vijver MJ, Reis-Filho JS. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010 Apr 08;29(14):2013–23. PMID: 20101236; PMCID: PMC2852518.; Cha JY, Maddileti S, Mitin N, Harden TK, Der CJ. Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform. Journal of Biological Chemistry. 2009 Mar;284(10):6227–40. doi: 10.1074/jbc.m803998200.; Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008 Apr 01;68(7):2340–8. doi: 10.1158/0008-5472.can-07-5229. PMID: 18381441.; Cha JY, Lambert QT, Reuther GW, Der CJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res. 2008 Mar;6(3):435–45. doi: 10.1158/1541-7786.mcr-07-0187. PMID: 18337450.; Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, Yamada Y, Tamura T, Fukuoka K, Kimura H, Saijo N, Nishio K. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res. 2007 May 15;13(10):3051–7. doi: 10.1158/1078-0432.ccr-06-2743. PMID: 17505008.; Shin E, Lee B, Yang J, Shin K, Lee G, Yun H, Song Y, Park SC, Kim E. Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. Journal of Cancer Research and Clinical Oncology. 2000 Aug 10;126(9):519–28. doi: 10.1007/s004320000128.; Tannheimer SL, Rehemtulla A, Ethier SP. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res. 2000;2(4):311–20. PMID: 11056689; PMCID: PMC13919.; Ueda T, Sasaki H, Kuwahara Y, Nezu M, Shibuya T, Sakamoto H, Ishii H, Yanagihara K, Mafune K, Makuuchi M, Terada M. Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. Cancer Res. 1999 Dec 15;59(24):6080–6. PMID: 10626794.; Lorenzi MV, Castagnino P, Chen Q, Chedid M, Miki T. Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations. Oncogene. 1997 Aug 14;15(7):817–26. doi: 10.1038/sj.onc.1201242. PMID: 9266968.; Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, Ishii H, Sakamoto H, Yamaguchi N, Yanagihara K, Hirohashi S, Sugimura T, Terada M. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res. 1996 Aug;2(8):1373–81. PMID: 9816310.